Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
New York Stock Exchange
Biotech
Preclinical eye disease biotech sets sights on $17M NYSE IPO
EIR Biopharma hopes to bring in $17.1 million from an IPO on the NYSE that could fund development of its preclinical eye disease drug.
James Waldron
Feb 18, 2026 8:55am
Fierce Pharma
Veradermics locks in $256M IPO, shares spike
Feb 5, 2026 10:01am
Evommune prices IPO amid government shutdown
Oct 30, 2025 12:34pm
New York Stock Exchange honors Fierce 15 winners
Sep 23, 2025 10:16am
Orthopedic implant maker Shoulder Innovations files $100M+ IPO
Jul 24, 2025 11:00am
Judge rules against investor trying to block Aurion IPO
Jan 28, 2025 2:54pm
